Vor Biopharma Inc
VORHealthcare|Biotechnology|USA
$19.14
-0.61 (-3.09%)
Earnings Power
$10.66
Financials
Financial Snapshot
Market Cap
$1.04B
Enterprise Value
$488.6M
Revenue (TTM)
$0.00
Net Income (TTM)
$-883.1M
Cash & Equivalents
—
Net Cash/Share
$-3.06
Free Cash Flow (TTM)
$-150.7M
Operating CF (TTM)
$-149.9M
Debt/Equity
-0.02
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$37.5M
Monthly Burn
$12.5M
Est. Runway
—
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $929.0K | $6.5M | $48.5M | $207.5M | $230.2M | $137.2M | $91.9M | $455.2M | $491.5M | |
| Operating Cash Flow | $-2.7M | $-9.9M | $-36.3M | $-69.1M | $-85.1M | $-100.3M | $-99.7M | $-142.7M | $-149.9M | |
| Free Cash Flow | $-2.7M | $-10.6M | $-40.5M | $-73.0M | $-93.6M | $-101.4M | $-99.9M | $-143.7M | $-150.7M | |
| Capital Expenditure | $0.00 | $-748.0K | $-4.2M | $-3.9M | $-8.5M | $-1.1M | $-229.0K | $-941.0K | $-758.0K | |
| Financing Cash Flow | $2.5M | $17.7M | $82.5M | $232.9M | $117.1M | $2.9M | $53.4M | $503.8M | $579.3M |
R&D Spending
R&D (TTM)
$312.4M
R&D Intensity
—
R&D Growth YoY
-2.8%
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $2.4M | $6.2M | $31.6M | $47.5M | $64.5M | $94.3M | $93.3M | $321.5M | $312.4M | |
| R&D % of Revenue | — | — | — | — | — | — | — | — | — | |
| SG&A | $427.0K | $4.2M | $11.7M | $21.5M | $28.9M | $31.7M | $27.9M | $50.1M | $61.1M |
Income Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $2.4M | $6.2M | $31.6M | $47.5M | $64.5M | $94.3M | $93.3M | $321.5M | $312.4M | |
| SG&A | $427.0K | $4.2M | $11.7M | $21.5M | $28.9M | $31.7M | $27.9M | $50.1M | $61.1M | |
| Operating Income | $-2.9M | $-10.4M | $-43.4M | $-69.0M | $-93.4M | $-126.0M | $-121.2M | $-371.6M | $-373.5M | |
| Interest Expense | $-1.0M | $-608.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $-4.2M | $-10.8M | $-43.3M | $-68.9M | $-92.1M | $-117.9M | $-116.9M | $-696.0M | $-883.1M | |
| Net Income | $-4.2M | $-10.8M | $-43.3M | $-68.9M | $-92.1M | $-117.9M | $-116.9M | $-696.0M | $-883.1M | |
| EPS (Diluted) | -14.67 | -20.66 | -28.44 | -42.00 | -46.60 | -35.00 | -34.03 | -70.50 | -333.44 | |
| EBITDA | $-3.1M | $-10.1M | $-42.8M | $-67.6M | $-90.9M | $-122.5M | $-117.7M | $-368.8M | $-371.4M | |
| Shares Out. (M) | 0.28 | 0.61 | 1.73 | 1.67 | 1.98 | 3.36 | 3.44 | 9.87 | 43.01 |
Balance Sheet
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $929.0K | $6.5M | $48.5M | $119.8M | $57.7M | $31.4M | $81.9M | $396.5M | $169.9M | |
| Marketable Securities | $0.00 | $0.00 | $0.00 | $87.7M | $172.5M | $105.8M | $10.0M | $58.7M | $321.7M | |
| Total Current Assets | $936.0K | $7.5M | $49.1M | $214.4M | $236.9M | $140.8M | $96.5M | $458.1M | $500.8M | |
| Total Assets | $1.0M | $9.8M | $75.9M | $242.6M | $299.4M | $198.1M | $142.9M | $464.1M | $506.7M | |
| Total Current Liabilities | $7.8M | $2.2M | $10.2M | $10.2M | $13.1M | $15.6M | $18.6M | $25.2M | $16.1M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $7.8M | $2.2M | $27.6M | $26.3M | $48.8M | $47.4M | $46.2M | $628.4M | $657.2M | |
| Stockholders' Equity | $-6.8M | $7.6M | $48.3M | $216.3M | $250.6M | $150.7M | $96.7M | $-164.3M | $-150.4M | |
| Retained Earnings | $-7.0M | $-17.9M | $-61.2M | $-130.1M | $-222.2M | $-340.1M | $-457.0M | $-1.15B | $-1.37B |
Cash Flow Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-2.7M | $-9.9M | $-36.3M | $-69.1M | $-85.1M | $-100.3M | $-99.7M | $-142.7M | $-149.9M | |
| Capital Expenditure | $0.00 | $-748.0K | $-4.2M | $-3.9M | $-8.5M | $-1.1M | $-229.0K | $-941.0K | $-758.0K | |
| Free Cash Flow | $-2.7M | $-10.6M | $-40.5M | $-73.0M | $-93.6M | $-101.4M | $-99.9M | $-143.7M | $-150.7M | |
| Investing Cash Flow | $0.00 | $-748.0K | $-4.2M | $-91.7M | $-94.1M | $71.0M | $96.9M | $-48.8M | $-311.8M | |
| Financing Cash Flow | $2.5M | $17.7M | $82.5M | $232.9M | $117.1M | $2.9M | $53.4M | $503.8M | $579.3M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $189.2M | $116.0M | $4.6M | $55.8M | $328.2M | $403.2M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $2.5M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $116.0K | $172.0K | $1.3M | $4.3M | $10.7M | $13.4M | $9.8M | $18.9M | $25.8M | |
| Net Change in Cash | $-197.0K | $7.1M | $42.1M | $72.1M | $-62.1M | $-26.3M | $50.6M | $312.3M | $117.6M |
Dilution Tracker
Shares outstanding grew 2472.5% over 5 years — significant dilution
Shares Outstanding
43M
5-Year Share Growth
+2472.5%
Stock Issuance (TTM)
$403.2M
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.28 | 0.61 | 1.73 | 1.67 | 1.98 | 3.36 | 3.44 | 9.87 | 43.01 | |
| YoY Change % | — | 115.5% | 183.9% | -3.5% | 18.3% | 69.9% | 2.3% | 187.3% | 335.7% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $189.2M | $116.0M | $4.6M | $55.8M | $328.2M | $403.2M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $116.0K | $172.0K | $1.3M | $4.3M | $10.7M | $13.4M | $9.8M | $18.9M | $25.8M |
Margins & Profitability
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| ROE % | 0.0% | -2483.2% | -155.0% | -52.1% | -39.5% | -58.7% | -94.5% | 0.0% | 0.0% | |
| ROA % | -412.3% | -200.1% | -101.1% | -43.3% | -34.0% | -47.4% | -68.6% | -229.3% | -302.1% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S—
Historical— / — / —
Industry Med.9.49
P/B—
Historical— / — / —
Industry Med.2.93
EV/EBITDA-1.48
Historical-1.48 / — / —
Industry Med.13.02
EV/Revenue—
Historical— / — / —
Industry Med.8.59
P/FCF—
Historical— / — / —
Industry Med.27.13
Intrinsic Value Models
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | N/A | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | - | - | - | - | - | 0.00 | |
| PB Ratio | 0.00 | 0.00 | 0.00 | 2.00 | 1.75 | 1.01 | 1.43 | 0.00 | 0.00 | |
| EV/EBITDA | 0.00 | 0.00 | 0.00 | -3.59 | -2.72 | -0.42 | -0.67 | -0.15 | -1.48 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
—
Distress
Piotroski F-Score
3
Weak
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $0.00M | $0.00M | $28.84M |
| Net Income | $-315.16M | $-198.15M | $-250.77M |
| EPS | -6.48 | -3.52 | -3.71 |
| Book Value per Share | -5.59 | -26.38 | -4.98 |
| Operating Cash Flow per Share | -2.84 | -3.14 | -3.32 |
| Operating CF | $-122.15M | $-135.06M | $-142.80M |